Incompatible natures of HIV-1 envelope in resistance to the CCR5 antagonist cenicriviroc and neutralizing antibodies.
Kuwata T, Enomoto I, Baba M, Matsushita S.
Antimicrob Agents Chemother. 2015 Nov 2
Abstract

FULL-TEXT ARTICLE
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
Visseaux B, Charpentier C, Collin G,
PLoS One. 2015 Aug 6;10(8):e0134904.
Paper

The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.
Kramer VG, Hassounah S, Colby-Germinario SP,
J Antimicrob Chemother. 2015 Mar;70(3):750-6.
Abstract

FULL-TEXT ARTICLE
Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc.
Kramer V, Hassounah S, Colby-Germinario S,
J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19531.
Paper

Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound.
Menning MM, Dalziel SM.
Mol Pharm. 2013 Nov 4;10(11):4005-15.
Abstract

FULL-TEXT ARTICLE
Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.
Kagan RM, Johnson EP, Siaw MF,  et al
AIDS Res Hum Retroviruses. 2014 Feb;30(2):151-9.
Paper

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in
HIV-1-Infected, Treatment-Experienced, CCR5 Antagonist-Naïve Subjects.
Lalezari J, Gathe J, Brinson C,  et al
J Acquir Immune Defic Syndr. 2011 Feb 11.
Abstract

Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.
Klibanov OM, Williams SH, Iler CA.
Curr Opin Investig Drugs. 2010 Aug;11(8):940-50
Abstract